RxDoctor Payments Data

Ramnik Xavier, MD

Gastroenterology · Boston, MANPI 1275523359

Payments from drug & device makers

What this record shows

This record is dominated by other: $528,610 of the $567,358 with a category attached, or 93.2%. AbbVie accounts for 93.2% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $440,229 and has fallen 79.9% since, to $88,381 in 2025. Among gastroenterology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$567,358in general payments, 2019–2025

Across 11 payments — averaging $51,578 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$529K
  • Novartis$39K
  • GSK$154
$13,707,100in research payments, 2019–2025

Across 14 payments — averaging $979,079 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson$9.3M
  • Janssen Research & Development, LLC$4.4M

What the payments were for

  • Consulting fees$38,5947%
  • Food & beverage$1540%
  • Other$528,61093%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie3$528,610
Novartis3$38,594
GSK5$154

How this compares

$567,358 in reported general payments places this provider in the 95th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$13,318
Medicare patients
86
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →